Efficacy and safety of PD-1/PD-L1 inhibitors combined with anti-angiogenic therapy for the unresectable hepatocellular carcinoma and the benefit for hepatitis B virus etiology subgroup: a systematic review and meta-analysis of randomized controlled trials

Table 2 The subgroup analysis for OS in patients with HCC

Subgroup		Number of studies	Pooled OS		Heterogeneity
Subgroup		Number of studies	HR[95% CI]	p	I²	p
Region	Asia	5	0.65[0.56, 0.76]	< 0.00001	0%	0.53
Region	Non-Asia	4	0.85[0.73, 0.98]	0.02	43%	0.15
AFP Lever	AFP < 400 ng/ml	4	0.75[0.65, 0.88]	0.0003	72%	0.01
AFP Lever	AFP ≥ 400 ng/ml	4	0.64[0.54, 0.77]	< 0.00001	0%	0.95
MVI or EHS	presence	5	0.67[0.59, 0.77]	< 0.00001	37%	0.17
MVI or EHS	absence	5	0.78[0.65, 0.92]	0.003	68%	0.01
BCLC Stage	BCLC B	4	0.64[0.52, 0.79]	< 0.00001	45%	0.14
BCLC Stage	BCLC C	4	0.70[0.61, 0.79]	< 0.00001	63%	0.04
Etiology	Hepatitis B	5	0.64[0.55, 0.74]	< 0.00001	0%	0.49
	Hepatitis C	4	0.81[0.64, 1.04]	0.1	58%	0.07
	Non-viral	4	0.91[0.75, 1.11]	0.37	0%	0.52

ISSN: 1471-2407